2023 annual financial data

Entrada Therapeutics, Inc. 2023 Operating margin

Entrada Therapeutics, Inc. 2023 operating margin with verified reported values.

Direct answer

Operating margin was -2.45%.

Operating income was -3,162,000 USD and net income was -6,685,000 USD.
Operating cash flow was 139,803,000 USD.

Get free Entrada Therapeutics, Inc. email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
129,013,000 USD
Operating income
-3,162,000 USD
Net income
-6,685,000 USD
Operating cash flow
139,803,000 USD